Cargando…

The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysis

INTRODUCTION: Multiple trials demonstrated that adding Bevacizumab to the standard neoadjuvant chemotherapy in HER-2 negative breast cancer increases pathological complete response. We conducted this meta-analysis to evaluate that effect on survival. METHODS: We performed a systematic search for ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alnimer, Yanal, Hindi, Zakaria, Katato, Khalil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077892/ https://www.ncbi.nlm.nih.gov/pubmed/30090017 http://dx.doi.org/10.1177/1178223418792250

Ejemplares similares

Factors associated with short recurrence-free survival in completely resected colon cancer
por: Alnimer, Yanal, et al.
Publicado: (2017)

Prediction of Liver Steatosis and Fibrosis Based on Clinical Variables Using a Large National Survey Database
por: Alnimer, Yanal, et al.
Publicado: (2023)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

Factors Associated with Worse Outcome in Early Stage Gastric Cancer Using the Surveillance, Epidemiology, and End Results (SEER) Database
por: Alnimer, Yanal, et al.
Publicado: (2020)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Synchronous endometrial adenocarcinoma and carcinosarcoma in endometrial polyp
por: Alnimer, Yanal, et al.
Publicado: (2018)

A case report of double negative anti-GBM disease
por: Kheiri, Babikir, et al.
Publicado: (2019)

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
por: Nakamoto, Shogo, et al.
Publicado: (2021)

Pathologic-Based Nomograms for Predicting Overall Survival and Disease-Free Survival Among Patients with Locally Advanced Rectal Cancer
por: Liu, Shuai, et al.
Publicado: (2021)

Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature
por: Alnimer, Yanal, et al.
Publicado: (2016)

Primary Idiopathic Osteoarthropathy: Could It Be Related to Alcoholism?
por: Alnimer, Yanal, et al.
Publicado: (2017)

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lux, Michael Patrick, et al.
Publicado: (2019)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
por: Quintela-Fandino, Miguel, et al.
Publicado: (2020)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
por: Chen, I-Chun, et al.
Publicado: (2021)

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
por: Gogate, Anagha, et al.
Publicado: (2023)

HER3 over-expression and overall survival in gastrointestinal cancers
por: Wang, Yadong, et al.
Publicado: (2015)

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Kaka, Nagham, et al.
Publicado: (2019)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
por: Kümmel, Sherko, et al.
Publicado: (2018)

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
por: Krishnan, Sreenath M., et al.
Publicado: (2021)

Association between obesity with disease-free survival and overall survival in triple-negative breast cancer: A meta-analysis
por: Mei, Lin, et al.
Publicado: (2018)

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
por: Nakamoto, Shogo, et al.
Publicado: (2022)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
por: Yoshimoto, Toshiaki, et al.
Publicado: (2020)

Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
por: Yamamoto, Takaya, et al.
Publicado: (2022)

Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival
por: Reichert, Verena M. C., et al.
Publicado: (2023)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
por: Carter, Tonia C., et al.
Publicado: (2018)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
por: Gleeson, Jack Patrick, et al.
Publicado: (2019)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival
por: Barrón-Gallardo, Carlos A., et al.
Publicado: (2022)

Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer
por: Verset, L, et al.
Publicado: (2013)

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
por: Sostelly, Alexandre, et al.
Publicado: (2019)

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
por: Chibaudel, Benoist, et al.
Publicado: (2020)

First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study()
por: Müller, Volkmar, et al.
Publicado: (2021)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
por: Sun, Zhengwu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nmq8qeod1u2hfapoj71v0kbuaa